NeuroNate said:

For Mindfulness and GLP-1 November, here is what the evidence says:The clinical trial data (SUSTAIN

I respect NeuroNate perspective but I think this oversimplifies things a bit. Re: Mindfulness and GLP-1 — the effect size varies considerably by population.

I am not saying NeuroNate wrong entirely — just that the picture is more nuanced than a blanket statement. The STEP data specifically shows dose-dependent variation.

Relevant to Mindfulness and GLP-1 — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 227 → 97 mg/dL, hsCRP 6.0 → 0.9 mg/L. All on tirzepatide for 7 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you PharmacoVig_BOS! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Mindfulness and GLP-1 but carl_compliance reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍